85 related articles for article (PubMed ID: 30919317)
1. Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study.
Temelkova N; Vladeva S; Delchev A; Ivanova K; Gerasimova-Zheleva Y; Kuneva T; Pehlivanova V; Popivanov P
Diabetes Ther; 2019 Jun; 10(3):981-993. PubMed ID: 30919317
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of lixisenatide for treatment of diabetes in the real world: data from the Monitoring Registry in a Real-Life Cohort in the Czech and Slovak Republic.
Haluzík M; Adamíková A; Běhunčík M; Macko M; Štěpánová R
Vnitr Lek; 2018; 64(4):357-366. PubMed ID: 29791170
[TBL] [Abstract][Full Text] [Related]
3. Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Patients with T2D Uncontrolled on NPH or Premixed Insulins as Part of Routine Clinical Practice in Bulgaria: ToUPGRADE Study.
Kamenov Z; Pehlivanova V; Kuneva T; Kirilov K; Bobeva R; Stoykova J; Mihalevska S
Diabetes Ther; 2021 Mar; 12(3):913-930. PubMed ID: 33604804
[TBL] [Abstract][Full Text] [Related]
4. Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis.
Shu H; Gu LN; Men LC; Lu JM
Diabetes Ther; 2016 Dec; 7(4):777-792. PubMed ID: 27796905
[TBL] [Abstract][Full Text] [Related]
5. Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.
Bonadonna RC; Blonde L; Antsiferov M; Berria R; Gourdy P; Hatunic M; Mohan V; Horowitz M
Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28303626
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.
Blüher M; Kurz I; Dannenmaier S; Dworak M
World J Diabetes; 2012 Sep; 3(9):161-9. PubMed ID: 23125906
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes.
Kis JT; Nagy G; Kovacs G
Diabetes Ther; 2021 Sep; 12(9):2517-2529. PubMed ID: 34357560
[TBL] [Abstract][Full Text] [Related]
8. Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study.
Brath H; Abrahamian H; Karuza T; Mihaljevic R; Pfohl M
Diabetes Ther; 2019 Apr; 10(2):451-462. PubMed ID: 30656523
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study.
Đekić D; Bojić M; Janež A; Klobučar S; Hadžimušović IG; Ković T; Mihalevska S
Diabetes Ther; 2023 Jul; 14(7):1217-1229. PubMed ID: 37211579
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data.
Raccah D
Expert Rev Endocrinol Metab; 2013 Mar; 8(2):105-121. PubMed ID: 30736171
[TBL] [Abstract][Full Text] [Related]
11. Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2).
Ghosh S; Tiwaskar M; Chawla R; Jaggi S; Asirvatham A; Panikar V
Diabetes Ther; 2020 Oct; 11(10):2257-2268. PubMed ID: 32779100
[TBL] [Abstract][Full Text] [Related]
12. Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies.
Feng W; Wang W; Meng R; Wu G; Zhang M; Zhang X; Yin H; Zhu D
BMJ Open Diabetes Res Care; 2021 Aug; 9(1):. PubMed ID: 34452904
[TBL] [Abstract][Full Text] [Related]
13. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
14. Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis.
Yao J; Zhang M; Zhang X; Zhang J
Diabetes Ther; 2023 Apr; 14(4):653-669. PubMed ID: 36809495
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
Caputo S; Maran A; Mannino D; Morano S; Lastoria G; Nicoziani P
Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
[TBL] [Abstract][Full Text] [Related]
17. Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.
Trujillo JM; Goldman J
Pharmacotherapy; 2017 Aug; 37(8):927-943. PubMed ID: 28556176
[TBL] [Abstract][Full Text] [Related]
18. Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo
Wiesli P; Schories M
Diabetes Ther; 2018 Dec; 9(6):2325-2334. PubMed ID: 30302721
[TBL] [Abstract][Full Text] [Related]
19. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
Gupta A
Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S.
Onishi Y; Niemoeller E; Ikeda Y; Takagi H; Yabe D; Seino Y
J Diabetes Investig; 2015 Mar; 6(2):201-9. PubMed ID: 25802728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
